Daniel Lischinsky - Endymed Founder and VP of RandD

ENDY Stock   330.00  2.00  0.60%   

Founder

Mr. Daniel Lischinsky will no longer serve as Chief Technology Officer and Vice PresidentDevelopment at Endymed Ltd effective April 22, 2018. He has held both roles at the Company since August 7, 2016. His work experience at the Company includes the following roles Chief Technology Officer since January 1, 2015 and Vice President Research Development from January 2, 2012. He holds a BS degree in Computer Science from The Technion Israel Institute of Technology. since 2016.
Age 48
Tenure 8 years
Phone855 363 9633
Webhttps://www.endymed.com

Endymed Management Efficiency

The company has return on total asset (ROA) of 0.0385 % which means that it generated a profit of $0.0385 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2146 %, meaning that it generated $0.2146 on every $100 dollars invested by stockholders. Endymed's management efficiency ratios could be used to measure how well Endymed manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 463 K in total debt with debt to equity ratio (D/E) of 7.1, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Endymed has a current ratio of 2.53, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Endymed until it has trouble settling it off, either with new capital or with free cash flow. So, Endymed's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Endymed sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Endymed to invest in growth at high rates of return. When we think about Endymed's use of debt, we should always consider it together with cash and equity.
Endymed Ltd, a medical technology company, designs, develops, and commercializes energy based medical aesthetic treatment systems for the professional and consumer markets worldwide. Endymed Ltd was founded in 2007 and is based in New York, New York. ENDYMED LTD operates under Medical Devices classification in Israel and is traded on Tel Aviv Stock Exchange. Endymed (ENDY) is traded on Tel Aviv Stock Exchange in Israel and employs 41 people.

Management Performance

Endymed Leadership Team

Elected by the shareholders, the Endymed's board of directors comprises two types of representatives: Endymed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Endymed. The board's role is to monitor Endymed's management team and ensure that shareholders' interests are well served. Endymed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Endymed's outside directors are responsible for providing unbiased perspectives on the board's policies.
Amir Schori, Vice President - Business Development
Lee Gabay, Controller
Ben Feldman, CFO
Rami Aviram, Vice President - Finance
Yossi CPA, Chief Officer
Yoram Hert, CEO, Endymed Medical Ltd.
Amiram Goldman, External Director
Eran Naor, External Director, Independent Director
Ronen Zadok, External Director
Amy Kamin, CEO of EndyMed USA
Elad Magal, CEO
Yoram Harth, Founder, Director & Chief Medical Officer
Yuan Yibing, Director
Sima Weissman, VP RD
Batsheva Elran, Director
Sima Witman, Vice President - Research & Development
Oren Maymon, Vice President - Operations
Lior Cohen, Vice President of Sales
Yosef BarOn, CEO
Joseph Levtzler, Clinical VP
Atzmon Shlush, Vice President - Operations
Eran Ishay, Vice President - Research & Development
Jan Jingran, Director
Sharon Dovev, Director of Marketing
Lior Vider, External Director
Daniel Lishinsky, Vice President - Research & Development
Idan Alfa, Finance Director
Yocheved Dvir, Director
Annie Jin, Director
Lee Roth, Finance Director
Zvika Lifschitz, Vice President - Finance
Ofer Zvi, Director
Bill Scott, Pres Inc
Daniel Lischinsky, Founder and VP of RandD
Moshe Cohen, Internal Auditor
Frank Iannelli, Corporate Executive
Amir Ganun, VP Marketing

Endymed Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Endymed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Endymed in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Endymed's short interest history, or implied volatility extrapolated from Endymed options trading.

Pair Trading with Endymed

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Endymed position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Endymed will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Endymed could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Endymed when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Endymed - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Endymed to buy it.
The correlation of Endymed is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Endymed moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Endymed moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Endymed can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Endymed. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Complementary Tools for Endymed Stock analysis

When running Endymed's price analysis, check to measure Endymed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Endymed is operating at the current time. Most of Endymed's value examination focuses on studying past and present price action to predict the probability of Endymed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Endymed's price. Additionally, you may evaluate how the addition of Endymed to your portfolios can decrease your overall portfolio volatility.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Bonds Directory
Find actively traded corporate debentures issued by US companies
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Please note, there is a significant difference between Endymed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Endymed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Endymed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.